Telmitar (Telmisartan)

Telmitar (Telmisartan) is a long-acting angiotensin II receptor blocker (ARB) prescription medication designed to manage hypertension and reduce cardiovascular risk in patients across the Philippines. This potent antihypertensive agent works by blocking the angiotensin II AT₁ receptor, which allows blood vessels to relax and dilate, effectively lowering systemic vascular resistance and maintaining stable blood pressure throughout a full 24-hour period.

What distinguishes Telmitar among ARB options is its extended half-life, providing consistent round-the-clock blood pressure control ideal for patients seeking reliable hypertension management. Beyond its primary blood pressure-lowering function, Telmitar is clinically approved for reducing cardiovascular morbidity and mortality in high-risk patients aged 55 and older, particularly those with established heart disease or type 2 diabetes who cannot tolerate ACE inhibitors.

Telmitar offers multiple therapeutic benefits. It relaxes and widens blood vessels to improve blood flow, significantly lowers the risk of heart attacks and strokes, and helps protect kidney function in diabetic patients. The medication exhibits a favorable metabolic profile, featuring mild peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist activity that may provide additional benefits in patients with insulin resistance.

Effective as monotherapy or in combination with other antihypertensive agents, Telmitar is widely recommended in international hypertension management guidelines. Common side effects may include dizziness, fatigue, back pain, or gastrointestinal upset. This medication is contraindicated in pregnancy and requires consistent dosing as directed by your healthcare provider, with periodic blood pressure and kidney function monitoring during treatment.